WaveMan
WaveMan · Company
KMDA · Kamada Ltd
> Search tickers & screens ⌘K
LIVE
← All companies

KMDA Kamada (KMDA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001567529
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
23
13F, latest reported quarter
Conversions, 180 days
8
Codes C/M, not in net · $563.5K priced

What the filings say about KMDA

Insiders, 180 days
-$1.7M net sold
1 seller · 0% of sales under a 10b5-1 plan

Kamada insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, KAMADA LTD insiders sold a net $1.7M of stock across 4 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Tsur David
Director
SELL
2026-09-17 SECtraded 2026-09-14
22,827
$186.7K
-10.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 9, 2026.
  • The trade is 5.6% of the 407,929 shares held after it.
  • No other insider sold within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Tsur David sold about $186.7K of KMDA on Sep 14, 2026; 23 funds added in the latest 13F quarter.
Tsur David
Director
SELL
2026-09-11 SECtraded 2026-09-09
175
$1.4K
-4.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 8, 2026.
  • The trade is 0.0% of the 430,756 shares held after it.
  • No other insider sold within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Tsur David sold about $1.4K of KMDA on Sep 9, 2026; 23 funds added in the latest 13F quarter.
Tsur David
Director
SELL
2026-09-11 SECtraded 2026-09-08
162,760
$1.3M
-4.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 7, 2026.
  • The trade is 37.8% of the 430,931 shares held after it.
  • No other insider sold within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Tsur David sold about $1.3M of KMDA on Sep 8, 2026, the largest insider sale at the company on our record; 23 funds added in the latest 13F quarter.
Tsur David
Director
SELL
2026-09-11 SECtraded 2026-09-07
14,238
$117.9K
-4.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.4% of the 593,691 shares held after it.
  • No other insider sold within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Tsur David sold about $117.9K of KMDA on Sep 7, 2026, the largest insider sale at the company on our record; 23 funds added in the latest 13F quarter.
4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.7M over 180 days
-$1.7M over 90 days
below 68% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
23 funds bought in last quarter
below 66% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.6% of the float short (float per yahoo 2026-10-27) · 2.5 days to cover · settled 2026-10-15
below 82% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch KMDA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+19.4%12M
-3%+10%+23%+36%2025-102025-122026-022026-042026-062026-082026-10 2026-09-08 · Tsur David sold $1.3M2026-09-14 · Tsur David sold $186.7K2026-09-07 · Tsur David sold $117.9K2026-09-09 · Tsur David sold $1.4K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KMDA: institutional holders (13F)

13F holdings, latest reported quarter
Phoenix Financial Ltd.
1,654,952 sh
$12.1M
RENAISSANCE TECHNOLOGIES LLC
742,418 sh
$5.4M
WELLS FARGO & COMPANY/MN
592,064 sh
$4.3M
DIMENSIONAL FUND ADVISORS LP
301,680 sh
$2.2M
ARK Investment Management LLC
263,304 sh
$1.9M

Congress trades in KMDA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KMDA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

KMDA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Nasdaq Biotechnology ETF
$23.9K position · as of 2026-05-31
0.0%
Dimensional International Small Cap Value ETF
$313.7K position · as of 2026-07-31
0.0%
Dimensional International Small Cap ETF
$304.0K position · as of 2026-07-31
0.0%
Dimensional International Core Equity 2 ETF
$200.5K position · as of 2026-07-31
0.0%
Dimensional World ex. U.S. Core Equity 2 ETF
$94.5K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.7M sold by insiders over 180 days, 23 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KMDA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
no equity line filed
Return on assets
+5.4%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Gross profit$76.4M$70.0M$55.5M$46.7M
Net income$20.2M$14.5M$8.3M-$2.3M
SEC XBRL, fiscal years, as known on 2026-10-28

KMDA Stock Sonar score 3/7 axes

Find similar shapesCompare

KMDA ranks highest on risk and compliance (84th percentile) and institutional and government (34th), and lowest on insider conviction (15th), among Pharma & Biotech peers.

Insider conviction
15
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.7M · 30 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
34
Inputs
  • Funds adding, latest quarter23 · 34 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
84
Inputs
  • Short interest, % of float+0.6% · 84 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
  • Profitability needs 2 of 4 inputs, 1 present: fewer than four consecutive quarters of operating income; no equity line filed
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

KMDA filings, in plain words

Are Kamada insiders buying or selling KMDA?

In the 180 days to 2026-10-28, Kamada insiders were net sellers, a net $1.7M across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Kamada insiders were net sellers of KMDA, a net $1.7M across purchases and sales reported on Form 4 by 1 seller. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies